DOCSLIB.ORG

Innovative Drug Platform & Formulation Technologies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Innovative Drug Platform & Formulation Technologies Parenteral Drug Delivery Market Trends Kurt R. Sedo Vice President, Operations PharmaCircle LLC Sunny Isles Beach, FL Parenteral Drug Delivery Market Trends • Pipeline/Products Overview • Device Based Technology Trends – Autoinjectors, pens, prefilled syringes, patch pumps… • Formulation Based Technology Trends – Targeted Delivery, Drug Conjugates, Injectable Depot • Other Technologies – Concentrated/Viscous, Stability, Injection Site Absorption Enhancers • Key Approvals in Last 5 years • Drug Delivery – Technologies, Deals, Analysis • Venture Capital Investments • Conclusions Overview: Innovator Products and Pipeline Route: Marketed vs Pipeline Marketed Products 14000 12000 DD Non-DD 38% 10000 62% 8000 6000 Marketed 4000 Pipeline Pipeline Programs 2000 0 DD 37% Non-DD 63% Drug Delivery Pipeline Analysis DD Pipeline by Phase/Route 4000 3500 DD Pipeline Moved to Clinic 3000 2017 - 2018 2500 900 Phase 3 2000 800 1500 Phase 2 700 600 1000 Phase 1 500 500 Preclinical 400 0 300 Research 200 2017 100 2018 0 Trends: 2017 Innovator Approvals 2017 Innovator Approvals by Route 70 60 50 40 30 20 FDA EMA 10 0 Trends: 2017 Innovator Approvals 2017 Innovator Approvals Injection Dosage Forms 70 60 50 40 30 FDA 20 EMA 10 0 Injection Injection Solution Injection Injection Injection Injection Lyophilized Lyophilized Suspension Emulsion Powder for Powder for Solution Suspension Key Product Sales: 2003, 2010, 2017 Blue highlight cells are injectable. Blue italics have injectable formulation available in franchise in that year. Overview/Trends: Injectables • Injectables Taking Over Pipeline Injection Device Approvals 2012-2018 • Devices, Devices, Devices… 180 – Multiple device strategies incorporated 160 140 into first approvals (e.g. Repatha, 120 Aimovig) 100 80 • Delivery of High Volume and/or 60 Viscous Biologics 40 20 • Trending Formulation Approaches 0 – Biologic Formulation Stabilization – Controlled Release SC/IM (e.g. Depot) – Controlled Release IV (e.g. PEG, Fc) – Targeted (ADC, Nanoparticles) – Nucleic Acid Delivery – Cell Therapy – Local Delivery Injectable Marketed Product Analysis Marketed Injectables by Indication 2500 2000 Marketed Injectables by Molecule Type 1500 carbohydrate Other antibody 5% 2% 1000 peptide 5% 500 7% 0 protein small 17% molecule 64% Injectable Marketed Product Analysis Marketed Injectables by Route Marketed Injectables by DD Category Infusion SC 8000 Intraarticular 1% 1% 7000 Intradermal Other 2% 6000 6% Infusion IV 5000 Injectable IV 28% 20% 4000 3000 Injectable IM Injectable SC 22% 2000 20% 1000 0 Injectable Pipeline Analysis Injectable Pipeline by Indication 6000 5000 Injectable Pipeline by Molecule Type 4000 other RNA oligo 2% 3000 gene 2% 3% 7% 2000 peptide 10% antibody 1000 32% 0 cell based 13% small molecule protein 18% 13% Injectable Pipeline Analysis Injectable Pipeline by Route Intravitreal 2% Injectable Pipeline by DD Category Other Intradermal 9000 11% 4% Infusion IV 8000 Injectable IM 34% 7000 10% 6000 5000 Injectable IV 4000 17% Injectable SC 3000 22% 2000 1000 0 Injectable Pipeline/Product Analysis Injectable Pipeline Dosage Form Emulsion Other 4% 2% Injectable Marketed Dosage Form Emulsion Lyo/Powder Suspension Other 1% 19% 8% 2% Solution Suspension 59% 16% Lyo/Powder 23% Solution 66% Evolution of Device Development Enbrel Present: Multiple Devices at Launch and Compressed LCM Repatha 1998 2004 2006 2017 Past: Devices as LCM Strategy 2015 2016 Injectable Nanoparticles Injectable Nanoparticles by Phase 400 350 300 250 Marketed 200 Approved 150 Registration 100 Phase 3 50 Phase 2 0 Phase 1 Preclinical Research Drug Conjugates Drug Conjugates by Phase 800 700 600 500 Marketed 400 Approved 300 Registration 200 Phase 3 100 Phase 2 0 Phase 1 Preclinical Research Injectable Depot Injectable Depot Products/Pipeline 250 200 150 Marketed 100 Reg/Approved Phase 3 50 Phase 2 0 Phase 1 Research/Pre Injectable Depot Injectable Depot Indications 250 200 150 100 50 0 LCM Case Study: Risperidone Product Approval LCM Risperdal Franchise (US) 5000 4500 Risperdal 1993 4000 Oral Tablet 3500 Risperdal 1996 3000 Risperdal Total Oral Solution 2500 Risperdal Injectable 2000 Risperdal Oral Risperdal M-Tab 2003 Sales WorldMil $ 1500 ODT 1000 500 Risperdal Consta 2003 Injectable (1 x 2 weeks) 0 Risperdal Consta utilizes MedisorbTM PLGA depot technology LCM Case Study: Paliperidone Product Approval LCM Paliperidone Franchise (US) 3500 Invega ER 2006 3000 Oral Tablet 2500 Invega Sustenna 2009 2000 Injectable (1 x month) Invega Total 1500 Invega Oral Invega Trinza 2015 World sales sales World $ Mil Invega Injectable Injectable (1 x 3 months) 1000 500 Paliperidone is active component of risperidone Invega ER utilizes OROSTM technology 0 Sustenna/Trinza utilize NanoCrystalTM Technology LCM Case Study: Risperidone Product Approval LCM Risperidone Franchise (US) 5000 Risperdal 1993 4500 Oral Tablet 4000 Risperdal 1996 Oral Solution 3500 Risperdal M-Tab 2003 3000 Franchise Total ODT 2500 Risperdal Total Risperdal Consta 2003 2000 Invega Total Injectable Sales WorldMil $ 1500 Invega ER 2006 1000 Oral Tablet 500 Invega Sustenna 2009 0 Injectable Invega Trinza 2015 Injectable Janssen: Risperdal/Invega Franchise Risperdal Tablet 1993 Risperdal Oral Solution 1996 Risperdal M-Tab 2003 Risperdal Consta 2003 Invega ER 2006 Invega Sustenna 2009 Invega Trinza 2015 Injectable High Concentration/Viscosity • Concentration/dose of injectable biologics (e.g. Mabs) is increasing resulting in need to deliver viscous/concentration solutions and suspensions. 350 300 250 200 Non-Cancer Cancer 150 100 50 0 <50 mg 50-100 mg 100-250 mg 250-500 mg >500 mg 1047 Mabs from Phase 1 to Market Notable Approvals: 2014 Product Notable HyQvia Injection Solution A novel formulation approach incorporating a proprietary (immunoglobulin G) enzyme to digest hyaluronic acid and permit a product normally administered by slow IV infusion to be delivered SC. Can be administered at home with portable infusion pumps. Other products approved with Halozyme’s Enhanze technology (Rituxan, Hercpetin). Neulasta OnPro The dose is administered over an extended period (empegfilgrastim) for improved tolerability. Compliance and convenience is also improved. Wearable/On body injector space very active. Notable Approvals: 2014 Product Notable Plegridy More oral treatments available for MS. (peginterferon beta-1a) Moves to dosing every 2 weeks. Available in patient friendly PFS and pen formats. Alprolix Protein-immunoglobulin fusions represent a next generation (eftrenonacog alfa) prodrug approach that blurs the line between protein engineering and traditional formulation. Notable Approvals: 2014 Product Notable Bydureon Dual Bydureon Dual provides incremental injectable delivery format/device (exenatide) convenience improvements that should translate into better compliance and therapeutic outcomes. New improved device approved in 2017. Evzio Effectively a multimedia delivery device, Evzio provides (naloxone) printed and audio dosing instructions to allow untrained individuals to quickly and effectively administer the dose. Reportedly easier to administer without training than nasal Narcan. Good press coverage but not necessarily translating into sales. Notable Approvals: 2014 Product Notable Xultophy Pen Combination product incorporates the latest generation Novo (insulin degludec, liraglutide) Nordisk dose-adjustable prefilled insulin syringe system providing easier use and greater accuracy. 1 X day dosing. Trulicity Pen Fc fused proteins in a patient friendly injection system intended (dulaglutide) to provide an extended duration of action (1 X week dosing) while encouraging patient compliance. Notable Approvals: 2014 Product Notable Copaxone Concentrated A simple lifecycle management high-dose formulation (glatiramer acetate) that enhances convenience and promises to extend the commercial prospects of the Copaxone franchise. Eloctate An Fc fusion protein for the treatment of hemophilia (efmoroctocog alfa) permitting an extended dosing interval of every four days for prophylaxis. Notable Approvals: 2015 Product Notable Adynovate PEG enabled product with twice weekly dosing versus 3-5 times (rurioctocog alfa pegol) a week. Onivyde Formulation may realize promise of liposomes and irinotecan in (irinotecan hydrochloride) a challenging indication. Notable Approvals: 2015 Product Notable Invega Trinza Logical lifecycle follow-on three month IM NanoCrystal (paliperidone palmitate) formulation to complement oral Invega ER Tablets (2006) and Invega Sustenna (2009) one month IM products for treatment of schizophrenia Aristada Prodrug approach to provide extended circulating levels of well (aripiprazole lauroxil) known drug aripiprazole. Dosing once every 4, 6, 8 weeks. Aristada Initio with NanoCrystalTM technology approved 2018 provides alternative regimen to initiate patients onto any dose of ARISTADA. Notable Approvals: 2015 Product Notable Duodopa Infuses a gel of levodopa/carbidopa into the jejenum via a (levodopa, carbidopa) percutaneous endoscopic gastrostomy with an outer transabdominal tube and an inner intestinal tube. $430 million sales in 2018. Repatha Autoinjector and PFS solutions for high cholesterol (evolocumab) management. Multi-device approval and launch. Wearable injector approved 2016. Notable Approvals: 2015 Product Notable Praluent In same space as Repatha but with a single injection once (alirocumab) every two weeks. Multi-device approval (PFS, Pen/Autoinjector). New device to deliver 300 mg dose, 1X monthly in one injection in Phase 3. Toujeo SOLOSTAR Successor
Load more

Recommended publications
  • Keeping up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A
    Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A. Shlom, PharmD, BCPS Senior Vice President & Director Clinical Pharmacy Program | Acurity, Inc. Privileged and Confidential April 10, 2019 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ▪ Identify orphan drugs and first-in-class medications approved by the FDA in 2018. ▪ List five new drugs and their indications. ▪ Identify the place in therapy for three novel monoclonal antibodies. ▪ Discuss at least two new medications that address public health concerns. Dr. Shlom does not have any conflicts of interest in regard to this presentation. Both trade names and generic names will be discussed throughout the presentation Privileged and Confidential 2018 NDA Approvals (NMEs/BLAs) ▪ Lutathera (lutetium Lu 177 dotatate) ▪ Braftovi (encorafenib) ▪ Vizimpro (dacomitinib) ▪ Biktarvy (bictegravir, emtricitabine, ▪ TPOXX (tecovirimat) ▪ Libtayo (cemiplimab-rwic) tenofovir, ▪ Tibsovo (ivosidenib) ▪ Seysara (sarecycline) alafenamide) ▪ Krintafel (tafenoquine) ▪ Nuzyra (omadacycline) ▪ Symdeko (tezacaftor, ivacaftor) ▪ Orilissa (elagolix sodium) ▪ Revcovi (elapegademase-lvir) ▪ Erleada (apalutamide) ▪ Omegaven (fish oil triglycerides) ▪ Tegsedi (inotersen) ▪ Trogarzo (ibalizumab-uiyk) ▪ Mulpleta (lusutrombopag) ▪ Talzenna (talazoparib) ▪ Ilumya (tildrakizumab-asmn) ▪ Poteligeo (mogamulizumab-kpkc) ▪ Xofluza (baloxavir marboxil) ▪ Tavalisse (fostamatinib disodium) ▪ Onpattro (patisiran)
    [Show full text]
  • CDER List of Licensed Biological Products With
    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA Yes 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761118 adalimumab-afzb Abrilada 11/15/19 B 761024 adalimumab-atto Amjevita 09/23/16 B 761059 adalimumab-bwwd Hadlima 07/23/19 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 017835 albumin chromated CR-51 serum Chromalbin 02/23/76 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 020304 aprotinin Trasylol 12/29/93 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17
    [Show full text]
  • Prior Authorization and Step Therapy Criteria
    BCN AdvantageSM HMO-POS and HMO BCN Advantage Comprehensive Formulary Prior Authorization / Step Therapy Program 2020 Plan Year Updated 12/1/2020 BCN Advantage HMO-POS and HMO monitor the use of certain medications to ensure our members receive the most appropriate and cost-effective drug therapy. Prior authorization (PA) for these drugs means that either clinical and/or administrative criteria must be met before coverage is provided. Drugs subject to step therapy (ST) may require previous treatment with one or more formulary drugs prior to coverage. Drugs that must meet clinical/administrative criteria are identified in the formulary list with (PA) or (ST). If drugs listed below have a (g) noted, the PA or ST criteria may also apply to the generic version of the drug. In some cases, the brand name drug is listed for reference and the generic drug is covered. Please refer to the Formulary to verify if your drugs are covered. Your physician can contact our pharmacy help desk to request prior authorization or step therapy for these drugs. The clinical criteria for authorization are based on current medical information and the recommendations of the Blues’ Pharmacy and Therapeutics Committee, a group of physicians, pharmacists and other experts. Please call the customer service number on the back of your BCN Advantage member ID card if you have questions about your drug coverage or a drug claim. g = generic available 12/1/2020 Page 1 of 35 FORM ID# 20165 H5883_20IndPAST_C FVNR 1120 MEDICATION/ DRUG CLASS CRITERIA Abilify Maintena® Coverage requires trial of oral aripiprazole. (aripiprazole) Coverage duration: Lifetime.
    [Show full text]
  • Drug Code List
    Blue Cross Blue Shield Arizonia Specialty Drug Code List HCPCS Generic Name Product Name Therapeutic Category Code 90281 Immune Globulin Gamastan Immune deficiency 90283 Immune Globulin Gammagard Immune deficiency 90284 Immune Globulin Cuvitru Immune deficiency 90378 Palivizumab Synagis RSV Polyneuropathy of hereditary transthyretin-mediated C9036 Patisiran Onpattro amyloidosis in adults. C9257 Bevacizumab Avastin Ophthalmic disorder C9399 Defibrotide Defitelio Other C9399 Elapegademase-lvlr Revcovi ADA-SCID (PKU) with uncontrolled blood phenylalanine C9399 Pegvaliase-pqpz Palynziq concentrations greater than 600 micromol/L on existing management C9399 Pasireotide Signifor Other C9399 Ravulizumab-cwvz Ultomiris PNH C9399 Unclassified drug or biological (new drug) Unclassified drug or biological (new drug) J0178 Aflibercept Eylea Ophthalmic disorder J0180 Agalsidase Beta Fabrazyme Lysosomal storage disorders J0202 Alemtuzumab Lemtrada Multiple sclerosis J0221 Alglucosidase Alfa Lumizyme Lysosomal storage disorders J0256 Alpha1-proteinase inhibitors Aralast NP, Prolastin-C, Zemaira Alpha-1 antitrypsin deficiency J0257 Alpha1-proteinase inhibitors Glassia Alpha-1 antitrypsin deficiency J0364 Apomorphine Apokyn Other J0517 Benralizumab Fasenra Severe Asthma with an Eosinophilic phenotye J0565 Bezlotoxumab Zinplava C-Diff J0584 Burosumab-twza Crysvita X-linked hypophosphatemia (XLH) J0585 OnabotulinumtoxinA Botox Spacticity disorder Updated: 3/13/2019 V1.2019 Effective: 1/1/2019 HCPCS Generic Name Product Name Therapeutic Category Code J0586
    [Show full text]
  • Mrx CLINICAL ALERT
    MRx NOVEMBER 2018 CLINICAL ALERT YOUR MONTHLY SOURCE FOR DRUG INFORMATION HIGHLIGHTS HOT TOPIC: While yearly vaccination is the primary NEW FLU MED APPROVED means of preventing and controlling EDITORIAL flu outbreaks, treatment with antiviral Influenza places a considerable burden agents can lessen symptoms, shorten STAFF on the United States (US) healthcare duration of illness, and prevent serious system, with up to 35 million cases complications. reported each year. As the 2018- EDITOR IN CHIEF 2019 flu season gets underway, the UPDATED CONSENSUS ON Maryam Tabatabai Food and Drug Administration (FDA) DIABETES MANAGEMENT PharmD granted Priority Review and approval for Genentech/Shionogi’s baloxavir The American Diabetes Association marboxil (Xofluza™), the first new (ADA) and the European Association for EXECUTIVE EDITOR novel influenza antiviral in nearly 20 the Study of Diabetes (EASD) updated Carole Kerzic years. The new agent is indicated to their 2015 joint position statement on RPh treat acute uncomplicated influenza the management of type 2 diabetes in people ≥ 12 years of age with flu mellitus (T2DM). It includes a new DEPUTY EDITORS symptoms for ≤ 48 hours. Baloxavir decision cycle for patient-centered Stephanie Christofferson marboxil uses a unique mechanism glycemic management with a goal PharmD of action to block the replication of to prevent diabetes complications influenza A and B viruses, including and enhance quality of life (QOL). Jessica Czechowski Avian strains (H7N9, H5N1). In clinical Greater focus is placed on lifestyle PharmD studies, it was well tolerated and management and diabetes self- eased flu symptoms in about the management education and support. Lara Frick same amount of time as the market Weight loss strategies include lifestyle, PharmD, BCPS, BCPP leader, oral oseltamivir (Tamiflu®), and medical nutrition therapy (MNT), significantly less time compared to medication, and surgical interventions.
    [Show full text]
  • Formulary Drug List
    ABALOPARATIDE Products Affected • TYMLOS PA Criteria Criteria Details Exclusion PATIENT HAS RECEIVED A TOTAL OF 24 MONTHS Criteria CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY. Required Medical Information Age Restrictions Prescriber Restrictions Coverage 12 MONTHS Duration 1 PA Criteria Criteria Details Other Criteria ONE OF THE FOLLOWING: (1) HIGH RISK FOR FRACTURES DEFINED AS ONE OF THE FOLLOWING: (A) HISTORY OF OSTEOPOROTIC (I.E., FRAGILITY, LOW TRAUMA) FRACTURE(S), (B) 2 OR MORE RISK FACTORS FOR FRACTURE (E.G., HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, BMD T-SCORE LESS THAN OR EQUAL TO -2.5, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS), OR (C) NO PRIOR TREATMENT FOR OSTEOPOROSIS AND FRAX SCORE OF AT LEAST 20% FOR ANY MAJOR FRACTURE OR OF AT LEAST 3% FOR HIP FRACTURE. (2) UNABLE TO USE ORAL THERAPY (I.E., UPPER GASTROINTESTINAL PROBLEMS UNABLE TO TOLERATE ORAL MEDICATION, LOWER GASTROINTESTINAL PROBLEMS UNABLE TO ABSORB ORAL MEDICATIONS, TROUBLE REMEMBERING TO TAKE ORAL MEDICATIONS OR COORDINATING AN ORAL BISPHOSPHONATE WITH OTHER ORAL MEDICATIONS OR THEIR DAILY ROUTINE). (3) ADEQUATE TRIAL OF, INTOLERANCE TO, OR A CONTRAINDICATION TO ONE BISPHOSPHONATE. Indications All FDA-approved Indications. Off Label Uses 2 ABATACEPT IV Products Affected • ORENCIA (WITH MALTOSE) PA Criteria Criteria Details Exclusion Criteria Required Medical Information Age Restrictions Prescriber RHEUMATOID ARTHRITIS AND POLYARTICULAR Restrictions JUVENILE IDIOPATHIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. Coverage INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. Duration Other Criteria INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF OR CONTRAINDICATION TO ANY TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, ENBREL, XELJANZ, RINVOQ.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Blue Cross and Blue Shield October 2020 Multi-Tier Basic Annual Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
    Multi-Tier Basic Annual Drug List October 2020 Please consider talking to your doctor about prescribing preferred medications, which may help reduce your out- of-pocket costs. This list may help guide you and your doctor in selecting an appropriate medication for you. The drug list is regularly updated. You can view the most up-to-date list, or the specialty drug list, at MyPrime.com. Contents Therapeutic Class Drug List Introduction ....................................................... I Anti-Infective Agents ........................................ 1 How drugs are selected .................................... I Antineoplastic Agents ...................................... 3 How member payment is determined ............... I Endocrine and Metabolic Drugs ...................... 6 How to use this list ........................................... II Cardiovascular Agents ................................... 11 Drugs used to treat multiple conditions ........... II Respiratory Agents ........................................ 16 Generic drugs ................................................. III Gastrointestinal Agents .................................. 18 Consider talking to your doctor about generic Genitourinary Agents ..................................... 20 drugs ........................................................... III Central Nervous System Drugs ..................... 20 Coverage considerations ............................... IV Analgesics and Anesthetics ........................... 24 Specialty drugs ..............................................
    [Show full text]
  • Potential and Applications of Nanocarriers for Efficient Delivery Of
    pharmaceutics Review Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals 1,2, 2, 1 1 1 Alam Zeb y , Isra Rana y, Ho-Ik Choi , Cheol-Ho Lee , Seong-Woong Baek , Chang-Wan Lim 1, Namrah Khan 2, Sadia Tabassam Arif 2, Najam us Sahar 2, Arooj Mohsin Alvi 2 , Fawad Ali Shah 2 , Fakhar ud Din 3, Ok-Nam Bae 1 , Jeong-Sook Park 4,* and Jin-Ki Kim 1,* 1 Institute of Pharmaceutical Science and Technology, College of Pharmacy, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan, Gyeonggi-do 15588, Korea; [email protected] (A.Z.); [email protected] (H.-I.C.); [email protected] (C.-H.L.); [email protected] (S.-W.B.); [email protected] (C.-W.L.); [email protected] (O.-N.B.) 2 Riphah Institute of Pharmaceutical Science, Riphah International University, Islamabad 44000, Pakistan; [email protected] (I.R.); [email protected] (N.K.); [email protected] (S.T.A.); [email protected] (N.u.S.); [email protected] (A.M.A.); [email protected] (F.A.S.) 3 Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan; [email protected] 4 Institute of Drug Research and Development, College of Pharmacy, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Korea * Correspondence: [email protected] (J.-S.P.); [email protected] (J.-K.K.); Tel.: +82-42-821-5932 (J.-S.P.); +82-31-400-5808 (J.-K.K.) These authors contributed equally to this work.
    [Show full text]
  • North Carolina Division of Health Benefits Physician Administered Drug Program Catalog
    North Carolina Division of Health Benefits Physician Administered Drug Program Catalog North Carolina Division of Health Benefits Physician Administered Drug Program Catalog •Unless otherwise indicated, the catalog contains procedure codes representing drugs, biologics, devices and vaccines which are only covered for FDA approved indications. Covered indications that are not FDA approved are identified with **. •11 digit National Drug Codes (NDCs) are required to be billed along with their corresponding procedure code. Drugs and biologics must be classified as CMS covered outpatient drugs from a labeler/manufacturer participating in the Medicaid Drug Rebate Program (MDRP). •The Max Daily Units for radiopharmaceuticals represents one therapeutic dose or diagnostic dose. •The HCPCS Code effective date represents the date the HCPCS code was established •Procedure codes for covered devices and vaccines are not required to be from a rebating labeler/manufacturer as they are not classified as covered outpatient drugs. HCPCS HCPCS HCPCS Code Billing FDA Approved Indications Max Monthly Gender NDC Rebating Labeler Last Modified Category HCPCS Description Effective Brand Name Generic Name Max Daily Units Minimum Age Maximum Age Comments Code Unit (See Package Insert for full FDA approved indication descriptions) Units Restrictions Required Required Date Date Injection, amphotericin B lipid amphotericin B lipid complex Drugs J0287 10 mg 1/1/2003 Abelcet® Indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. 70 2,170 N/A N/A N/A Y Y 5/6/2019 complex, 10 mg injection aripiprazole extended-release Injection, aripiprazole, Indicated for the treatment of schizophrenia in adults.
    [Show full text]
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
    Effective 6/11/2020. Contact [email protected] for previous versions. Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline Note: Active Table of Contents – Click to follow link INTRODUCTION........................................................................................................................... 3 SCOPE....................................................................................................................................... 3 DEFINITIONS .............................................................................................................................. 3 RECOMMENDATIONS ................................................................................................................... 4 METHODOLOGY .........................................................................................................................28 COLLATERAL TOOLS & RESOURCES..................................................................................................31 APPENDIX A: PERIOPERATIVE MEDICATION MANAGEMENT .................................................................32 APPENDIX B: TREATMENT ALGORITHM FOR THE TIMING OF ELECTIVE NONCARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS .....................................................................................................................58 APPENDIX C: METHYLENE BLUE AND SEROTONIN SYNDROME ...............................................................59 APPENDIX D: AMINOLEVULINIC ACID AND PHOTOTOXICITY
    [Show full text]
  • CDER List of Licensed Biological Products With
    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761024 adalimumab-atto Amjevita 09/23/16 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17 103764 basiliximab Simulect 05/12/98 NA NA 103691 becaplermin Regranex 12/16/97 NA NA 125288 belatacept Nulojix 06/15/11 125370 belimumab Benlysta 03/09/11 761043 belimumab Benlysta
    [Show full text]